Esperion Therapeutics (ESPR) Stock
Biotech company selling oral medicines to lower cholesterol. Here's the price, business snapshot, and what's worth knowing about Esperion Therapeutics in September 2026.
Esperion Therapeutics, Inc. (ESPR) is a US-based biotechnology company focused on lowering LDL cholesterol through oral therapies, principally bempedoic acid marketed as Nexletol and the combination Nexlizet. As a small‑cap, commercial-stage player (market capitalisation about $647.7 million), Esperion generates revenue from product sales while continuing to invest in clinical development and market access. Investors should note that growth depends on physician and patient adoption, pricing and reimbursement decisions, and the outcome of ongoing clinical and regulatory activity. The company faces established competition from statins and newer injectable therapies, which can influence market share. Financial results and the share price can be volatile for biotech firms of this size, often driven by trial data, sales trends and financing events. This summary is for general, educational purposes only and is not personal investment advice; suitability depends on your objectives, timeframe and risk tolerance.
About This Stock
ESPERION THERAPEUTICS INC
ESPR
Current Price
$3.20
Potential 12 Month Profit
65.96%
Sector
Healthcare
Industry
Pharmaceuticals
Ticker
ESPR
Market Cap
$819.46M
Potential 12 Month Profit
65.96%
Sector
Healthcare
Industry
Pharmaceuticals
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Esperion's stock, believing it could reach a higher price soon.
Financial Health
ESPERION is performing well, with strong revenue and profits, indicating healthy financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Commercial traction
Products are on the market and sales growth will reflect physician adoption and payer support; revenue can be uneven and subject to market dynamics.
Mechanism & pipeline
Bempedoic acid offers an oral mechanism for lowering LDL and there are ongoing studies; trial results and regulatory updates may materially change prospects.
Competitive landscape
Operates in a large but competitive lipid‑lowering market where statins and injectables are established; pricing and new entrants are important risks to monitor.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.